Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01995188 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
A Phase 1 study of Non-squamous Non-small Cell Lung Cancer, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 4
- Study locations
NCT01995188 is a Phase 1 study of Non-squamous Non-small Cell Lung Cancer that has completed, run by Genentech. The registered enrollment target is 41 participants, below the 398-participant average among 7 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT01995188, a Phase 1 study of Non-squamous Non-small Cell Lung Cancer, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 4
- Study locations
Study Summary
This open-label, multicenter, phase 1b study will evaluate the safety and pharmacokinetics of DNIB0600A in participants with platinum-sensitive ovarian cancer (PSOC) or Non-Squamous Non-small Cell Lung Cancer (NSCLC). The maximum tolerated dose of intravenously infused DNIB0600A in combination with carboplatin will be determined in escalating dose cohorts. The combination of DNIB0600A and carboplatin will then be evaluated with and without bevacizumab \[Avastin\] in three dose expansion cohorts.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG DNIB0600A
Study Locations (4)
Massachusetts
- Massachusetts General Hospital. - Boston
- Dana Farber Cancer Inst. - Boston
Oklahoma
- The University of Oklahoma - Oklahoma City
Tennessee
- The Sarah Cannon Research Inst - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2013-12-16 |
| Est. Completion | 2016-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01995188
The ClinicalTrials.gov registry entry for NCT01995188 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 398-participant average among 7 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-squamous Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01995188 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Oklahoma, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01995188 about?
NCT01995188 is a clinical study titled "A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer". This open-label, multicenter, phase 1b study will evaluate the safety and pharmacokinetics of DNIB0600A in participants with platinum-sensitive ovarian cancer (PSOC) or Non-Squamous Non-small Cell Lung Cancer (NSCLC). The maximum tolerated dose of intravenously infused DNIB0600A in combination with ...
What is the current status of trial NCT01995188?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2013-12-16. Estimated completion is 2016-11-09.
What conditions does trial NCT01995188 study?
This clinical trial studies the following conditions: Non-squamous Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT01995188?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), DNIB0600A (DRUG).
Who is sponsoring clinical trial NCT01995188?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01995188 being conducted?
This trial has 4 study locations across Massachusetts, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-squamous Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
RECRUITING · Phase 3
-
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
Phase III Study of AK112 for NSCLC Patients
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
COMPLETED · Phase 3
-
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.